| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 11/18/2010 | US20100291068 Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| 11/18/2010 | US20100291044 Lunasin-induced regulation of disease-related gene expression |
| 11/18/2010 | US20100291043 Il-12 immunotherapy for cancer |
| 11/18/2010 | US20100291036 Compositions and methods for modulating vascular endothelial growth factor c (vegf-c) expression |
| 11/18/2010 | US20100291033 Albumin Fusion Proteins |
| 11/18/2010 | US20100291030 Use of il-28 and il-29 to treat cancer and autoimmune disorders |
| 11/18/2010 | US20100291027 Hyaluronic acid (ha) injection vehicle |
| 11/18/2010 | US20100291025 Indazole inhibitors of tyrosine kinase |
| 11/18/2010 | US20100291021 Aliphatic prodrug linker |
| 11/18/2010 | US20100291020 Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors |
| 11/18/2010 | US20100291003 Histone deacetylase inhibitors |
| 11/18/2010 | US20100291001 Metalloproteinase-binding proteins |
| 11/18/2010 | US20100290994 O-Methylated Rapamycin Derivatives For Alleviation And Inhibition Of Lymphoproliferative Disorders |
| 11/18/2010 | US20100290993 Antibodies to IL-6 and use thereof |
| 11/18/2010 | US20100290989 Compositions affecting hyaluronic acid mediated activity |
| 11/18/2010 | US20100290984 Anti-mrp3 antibodies and methods of use |
| 11/18/2010 | US20100290983 Compositions and Methods for Drug Delivery |
| 11/18/2010 | US20100290982 Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles |
| 11/18/2010 | DE102009022046A1 Entfärbte Extrakte der Pflanze Pandanus conoideus Discolored extracts of the plant Pandanus conoideus |
| 11/18/2010 | CA2799081A1 Vaccine immunotherapy |
| 11/18/2010 | CA2763347A1 Methods for treatment of disease using an epimetabolic shifter (coenzyme q10) |
| 11/18/2010 | CA2762107A1 Sublingual dexmedetomidine compositions and methods of use thereof |
| 11/18/2010 | CA2761946A1 Carcinoma diagnosis and treatment, based on odc1 genotype |
| 11/18/2010 | CA2761940A1 Methods of treating proliferative diseases |
| 11/18/2010 | CA2761891A1 Anti-axl antibody |
| 11/18/2010 | CA2761880A1 2'-fluoro arabino nucleosides and use thereof |
| 11/18/2010 | CA2761845A1 Thiophene[3,4-c]pyrrole pde4 mediators |
| 11/18/2010 | CA2761801A1 Compositions and methods for drug delivery |
| 11/18/2010 | CA2761717A1 Methods for treatment of oncological disorders using epimetabolic shifters, multdimensional intracellular molecules, or environmental influencers |
| 11/18/2010 | CA2761628A1 New medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity |
| 11/18/2010 | CA2761627A1 Sulphated hyaluronic acids as regulator agents of the cytokine activity |
| 11/18/2010 | CA2761605A1 Use of lipid conjugates in the treatment of diseases associated with vasculature |
| 11/18/2010 | CA2761438A1 Compositions and methods for treating hematologic cancers targeting the sirp-.alpha.-cd47 interaction |
| 11/18/2010 | CA2761393A1 Ttk peptides and vaccines including the same |
| 11/18/2010 | CA2761256A1 Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
| 11/18/2010 | CA2761243A1 Anti-tumor agent containing tegafur-gimeracil-oteracil potassium combination drug and oxaliplatin |
| 11/18/2010 | CA2760778A1 Heteroaryl compounds as pikk inhibitors |
| 11/18/2010 | CA2760179A1 Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound |
| 11/18/2010 | CA2759884A1 [1,2,4] triazolo [4,3-b] pyridazines as ligands of the androgen receptor |
| 11/18/2010 | CA2759836A1 Humanized axl antibodies |
| 11/17/2010 | EP2251695A2 Markers associated with endometrial disease |
| 11/17/2010 | EP2251357A1 Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor |
| 11/17/2010 | EP2251355A1 Treatment with anti-VEGF antibodies |
| 11/17/2010 | EP2251350A2 RORalpha promoting the induction of Bmal1 |
| 11/17/2010 | EP2251344A1 Formulation of boronic acid compounds |
| 11/17/2010 | EP2251341A1 Heterocyclic Janus kinase 3 inhibitors |
| 11/17/2010 | EP2251340A1 Substituted tetrahydro-1h-pyrazolo[3,4-c] pyridines, compositions containing same and use thereof |
| 11/17/2010 | EP2251332A1 The aromatic ring triazine derivatives and the uses thereof |
| 11/17/2010 | EP2251327A2 Heterocyclic inhibitors of MEK and methods of use thereof |
| 11/17/2010 | EP2251042A2 Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors |
| 11/17/2010 | EP2251040A1 Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype |
| 11/17/2010 | EP2251039A2 Oligo double-stranded rna inhibiting the expression of bcl-2 and pharmaceutical composition containing the same |
| 11/17/2010 | EP2251025A1 Use of inclusion bodies as therapeutic agents |
| 11/17/2010 | EP2251019A1 Agent for prevention of alcoholic hepatopathy |
| 11/17/2010 | EP2251015A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
| 11/17/2010 | EP2251014A1 Combined use of cholestanol derivative |
| 11/17/2010 | EP2251013A2 Use of inositol-tripyrophosphate in treating Alzheimer's disease, stroke or osteoporosis |
| 11/17/2010 | EP2250504A2 Use of fsh receptor ligands for diagnosis and therapy of cancer |
| 11/17/2010 | EP2250278A2 Methods and compositions related to peptides and proteins with c-terminal elements cross-reference to related applications |
| 11/17/2010 | EP2250201A1 Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy |
| 11/17/2010 | EP2250189A1 Glycopeptides and methods of making and using them |
| 11/17/2010 | EP2250181A1 Ruthenium compounds and compositions |
| 11/17/2010 | EP2250173A1 Imidazopyrazinol derivatives for the treatment of cancers |
| 11/17/2010 | EP2250160A1 Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| 11/17/2010 | EP2250155A1 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors |
| 11/17/2010 | EP2250152A1 Quinolines as inhibitors of farnesyl pyrophosphate synthase |
| 11/17/2010 | EP2249865A2 Breaking immunological tolerance with a genetically encoded unnatural amino acid |
| 11/17/2010 | EP2249859A1 Treatment of metastatic stage prostate cancer with degarelix |
| 11/17/2010 | EP2249858A1 Method of treating prostate cancer with the gnrh antagonist degarelix |
| 11/17/2010 | EP2249852A2 Soluble complexes of curcumin |
| 11/17/2010 | EP2249845A2 Selective agonist of toll-like receptor 3 |
| 11/17/2010 | EP2249844A1 Active substance combination with gemcitabine for the treatment of epithelial cancer |
| 11/17/2010 | EP2249838A1 Pharmaceutical solid state forms |
| 11/17/2010 | EP2249832A1 Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds |
| 11/17/2010 | EP2249831A2 Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| 11/17/2010 | EP2249827A1 Use of picoplatin and cetuximab to treat colorectal cancer |
| 11/17/2010 | EP2249826A1 Compositions and methods of use of compounds to increase cancer patient survival time |
| 11/17/2010 | EP2249821A1 Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs |
| 11/17/2010 | EP2249644A2 Picoplatin and amrubicin to treat lung cancer |
| 11/17/2010 | EP1959955B1 Method of treating abnormal cell growth |
| 11/17/2010 | EP1928861B1 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
| 11/17/2010 | EP1896491B1 Monoazole ligand platinum analogs |
| 11/17/2010 | EP1896399B1 Biphenyl and naphthyl-phenyl hydroxamic acid derivatives |
| 11/17/2010 | EP1565489B1 Internalizing antibodies specific for the RAAG10 cell surface target |
| 11/17/2010 | EP1491206B1 Use of peptide derivatives for inducing cell differentiation |
| 11/17/2010 | EP1204682B1 Compositions and methods for the treatment of tumors |
| 11/17/2010 | CN1927400B Biomagnetism nano target anti-cancer drug and its preparation |
| 11/17/2010 | CN1772089B Freeze dried oldenlandia powder for injection and its preparation method |
| 11/17/2010 | CN101889015A Pyrimidine substituted purine derivatives |
| 11/17/2010 | CN101889009A Inhibitors of c-fms kinase |
| 11/17/2010 | CN101889008A Quinoline derivatives for modulating DNA methylation |
| 11/17/2010 | CN101889007A Method for amplifying hematopoietic stem cells using heterocyclic compound |
| 11/17/2010 | CN101888878A Novel antibodies |
| 11/17/2010 | CN101888856A Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| 11/17/2010 | CN101888855A Cancer remedy containing antibody against peptide encoded by exon-17 of periostin |
| 11/17/2010 | CN101888852A 癌症疫苗组合物 Cancer vaccine composition |
| 11/17/2010 | CN101886115A Application of three microRNAs in diagnosis and treatment of human acute myeloid leukemia |
| 11/17/2010 | CN101886090A Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof |
| 11/17/2010 | CN101885784A Method for producing glucomannan by liquid culture of konjac cells |
| 11/17/2010 | CN101885778A HPV (Human Papilloma Virus) 16 type L2N120E7E6 fusion protein, gene, preparation method and application |